TY - JOUR T1 - Excess Mortality in the United States During the First Peak of the COVID-19 Pandemic JF - medRxiv DO - 10.1101/2020.05.04.20090324 SP - 2020.05.04.20090324 AU - R. Rivera AU - J. E. Rosenbaum AU - W. Quispe Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/27/2020.05.04.20090324.abstract N2 - Deaths are frequently under-estimated during emergencies, times when accurate mortality estimates are crucial for pandemic response and public adherence to non-pharmaceutical interventions. This study estimates excess all-cause, pneumonia, and influenza mortality during the COVID-19 health emergency using the June 12, 2020 release of weekly mortality data from the United States (U.S.) Mortality Surveillance Survey (MSS) from September 27, 2015 to May 9, 2020, using semiparametric and conventional time-series models in 9 states with high reported COVID-19 deaths and apparently complete mortality data: California, Colorado, Florida, Illinois, Massachusetts, Michigan, New Jersey, New York, and Washington. The May 9 endpoint was chosen due to apparently increased reporting lags in provisional mortality counts. We estimated greater excess mortality than official COVID-19 mortality in the U.S. (excess mortality 95% confidence interval (CI) (80862, 107284) vs. 78834 COVID-19 deaths) and 6 states: California (excess mortality 95% CI (2891, 5873) vs. 2849 COVID-19 deaths); Illinois (95% CI (4412, 5871) vs. 3525 COVID-19 deaths); Massachusetts (95% CI (5061, 6317) vs. 5050 COVID-19 deaths); New Jersey (95% CI (12497, 15307) vs. 10465 COVID-19 deaths); and New York (95% CI (30469, 37722) vs. 26584 COVID-19 deaths). Conventional model results were consistent with semiparametric results but less precise.Official COVID-19 mortality substantially understates actual mortality, suggesting greater case-fatality rates. Mortality reporting lags appeared to worsen during the pandemic, when timeliness in surveillance systems was most crucial for improving pandemic response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNSF OAC 1940179Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval was not necessaryAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData comes from National Center for Health Statistics and is available to the public: https://gis.cdc.gov/grasp/fluview/mortality.html https://github.com/bakuninpr/Estimating-Excess-Deaths-in-the-United-States-Early-in-the-COVID-19-Pandemic NCHSNational Center for Health StatisticsUSUnited StatesCIconfidence intervalsMSSMortality Surveillance System ER -